曲美他嗪对扩张型心肌病心力衰竭患者心功能疗效观察.docVIP

曲美他嗪对扩张型心肌病心力衰竭患者心功能疗效观察[摘要] 目的：观察曲美他嗪治疗扩张型心肌病（DCM） 合并心力衰竭的临床价值。方法：100例DCM合并心力衰竭患者随机分为观察组和对照组，对照组给予常规抗心力衰竭治疗, 观察组在常规治疗的基础上加用曲美他嗪治疗。观察治疗前和治疗24周后患者心功能分级及左室射血分数（LVEF）、左室舒张末期内径（LVEDD）、每分心排量（CO）的变化。结果：治疗24周后, 对照组总有效率为72.00%（36/50），观察组总有效率为88.00%（44/50），两者比较差异有统计学意义（P＜0.05）；两组治疗后LVEDD、CO、LVEF均较治疗前显著改善（P＜0.01），且观察组治疗后上述指标明显优于对照组（P＜0.01或P＜0.05）。结论：曲美他嗪可以安全有效地改善DCM合并心力衰竭患者的心功能，值得临床推广。 [关键词] 曲美他嗪；扩张型心肌病；心力衰竭；心功能 [中图分类号] R942.2 [文献标识码]B[文章编号]1674-4721（2011）05（c）-062-02 Clinical therapeutic effectiveness of trimetazidine on the treatment of patients with dilated cardiomyopathy associated with chronic congestive heart failure YANG Haitao, ZHENG Huafeng, HUANG Peng Cardiology-vesicular Department, Shenzhen Hospital Peking University， Guangdong Province, Shenzhen 518036,China [Abstract] Objective: To explore the clinical therapeutic effectiveness of trimetazidine on the treatment of dilated cardiomyopathy( DCM) associated with chronic congestive heart failure(CHF). Methods: 100 patients with DCM associated with CHF were randomly divided into control group and observation group. Patients in the control group were given routinely treated. Patients in the observation group were treated with trimetazidine on the basis of the routine treatment. The course of treatment lasted 24 weeks. The grade of cardiac function, left ventricular ejection fraction(LVEF),left ventricular end diastolic diameter (LVEDD) and cardiac output (CO)were determined before and after 24 weeks after treatment in both groups. Results:After 24 weeks of treatment, the total effective rate in the control group was 72.00% (36/50), and in the observation group was 88.00% (44/50), the difference was statistically significant(P 1.4 统计学分析 采用SPSS 13.0统计学软件，计量资料采用均数±标准差（x±s）表示，均数的比较采用t检验，率的比较采用χ2 检验，以P＜0.05为差异有统计学意义。 2 结果 2.1 两组治疗效果的比较 治疗24周后，对照组显效8例，有效28例，无效14例，总有效率为72.00%（36/50），观察组显效13例，有效31例，无效6例，总有效率为88.00%（44/50），两者比较差异有统计学意义（P＜0.05）。结果详见表1。 2.2 治疗前后两组超声心动图指标的比较 观察组治疗后LVE